In CML bone marrow samples derived from patients resistant to imatinib, due to BCR-ABL T315I point mutation, a pro-apoptotic effect of CK2 inhibition was reported, mediated by PTEN reactivation [85]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.